Wealth Management

Annuities have long been seen as one of the financial world’s most perplexing instruments, puzzling both retirees and economists alike. While economic models suggest that annuities should be a cornerstone of retirement planning due to their ability to provide lifelong income and protect against outliving savings, actual adoption rates have historically been low. 

 

Recently, however, there has been a notable rise in annuity sales, particularly for fixed products, which offer guaranteed returns and shield investors from market volatility. This shift may stem from concerns over Social Security’s future, the allure of secure income in uncertain times, and a growing desire among retirees to balance spending confidence with preserving wealth. 



Over time, the annuity landscape has expanded into a spectrum of offerings, including fixed, variable, and hybrid products, tailored to meet varying financial goals and preferences. 

 


 

Finsum: As these products gain prominence, they demand a deeper understanding from advisors guiding clients through estate and retirement planning.

 

Over the past year, the U.S. stock market has risen by an impressive 30%, despite a recent 2.1% drop. This robust growth highlights opportunities in high-growth tech stocks that excel in innovation and scalability. 

 

Companies like PowerFleet stand out, forecasting a 29.7% annual revenue growth and significant earnings improvement due to strategic expansions such as its Fleet Complete acquisition. Live Nation Entertainment also shines, with substantial revenue driven by concerts, ticketing, and sponsorships, leveraging its global presence to dominate the live entertainment industry. 

 

Meanwhile, Triumph Group has gained investor attention with a 66.9% one-year stock increase, supported by upward earnings revisions and strong fundamentals. 


Finsum: These examples underscore the dynamic potential of select tech and entertainment stocks in the current market.

 

The healthcare sector faced significant turbulence following President-elect Donald Trump’s announcement of Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Kennedy’s longstanding skepticism about vaccines has sparked concerns about its impact on public health and industry stability, leading to sharp declines in shares of vaccine producers like Moderna and Pfizer. 

Analysts suggest his leadership could reshape regulatory frameworks, adding uncertainty for pharmaceutical companies and possibly affecting vaccine uptake. Biotech firms also saw notable losses, while psychedelic therapy companies experienced gains, bolstered by Kennedy’s apparent openness to advancing their approval process. 

Meanwhile, the medical technology sector showed relative resilience, though experts caution that indirect impacts could still emerge. As Kennedy prepares to oversee critical agencies like the FDA and CDC, the industry braces for policy changes that could redefine its landscape.


Finsum: Don’t undersell the impact of inertia in regulatory process and now one might capitalize on a dip in health stocks. 

 

Page 1 of 302

Contact Us

Newsletter

Subscribe

Subscribe to our daily newsletter

Top